e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Annovis Bio, Inc. Common Stock (NY:ANVS)

2.250 +0.020 (+0.90%)

Streaming Delayed Price Updated: 9:54 AM EDT, Apr 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Annovis Bio, Inc. Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

17 18 Next >

Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday ↗

September 13, 2022

Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

September 12, 2022

Via Benzinga

FDA Gives Green Signal To Annovis Bio's Parkinson's Trial With Buntanetap ↗

July 07, 2022

Via Benzinga

Why Immunocore Shares Dipped 22%; Here Are 73 Biggest Movers From Friday ↗

September 12, 2022

Gainers Digital Media Solutions, Inc. (NYSE: DMS) shares climbed 71.9% to close at $2.20 on Friday after the company received a non-binding go-private proposal from Prism Data for $2.50 per share in...

Via Benzinga

Why Zscaler Is Trading Higher By Around 19%, Here Are 44 Stocks Moving In Friday's Mid-Day Session ↗

September 09, 2022

Gainers Digital Media Solutions, Inc. (NYSE: DMS) shares jumped 70% to $2.1750 after the company received a non-binding go-private proposal from Prism Data for $2.50 per share in cash.

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

September 09, 2022

Via Benzinga

Why ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday ↗

September 09, 2022

Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 176.5% to close at $31.00 on Thursday after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2022 ↗

September 08, 2022

Via Benzinga

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary ↗

August 24, 2022

Via Benzinga

Annovis Shares Gain As Late-Stage Parkinson's Disease Study Takes-off ↗

August 24, 2022

Annovis Bio, Inc. (NYSE: ANVS) has initiated patient dosing in the Phase 3 clinical trial evaluating buntanetap in early Parkinson's Disease (PD). The Phase 3 trial is designed to evaluate the...

Via Benzinga

Publication Of Peer-Reviewed Study In Journal Of The Alzheimer's Association Could Mark A Significant Step For Longeveron ↗

August 02, 2022

Recent publishing of Longeveron Inc.’s (NASDAQ: LGVN)

Via Benzinga

Dear AMC Stock Fans, Mark Your Calendars for Aug. 4 ↗

July 07, 2022

AMC Entertainment (AMC) stock is in the news today as investors in the theater company prepare for a potential catalyst coming next month!

Via InvestorPlace

Annovis Bio (ANVS) Stock Soars 6% on Positive FDA Update ↗

July 07, 2022

Annovis Bio (ANVS) stock is soaring higher on Thursday following a positive update from the FDA for its buntanetap clinical trial.

Via InvestorPlace

Annovis Bio Gets FDA Nod For Late-Stage Parkinson Disease Study Amendments ↗

July 07, 2022

The United States Food and Drug Administration (FDA) announced clearance for amendments to Annovis Bio’s (NYSE: ANVS) Phase 3 clinical study of Buntanetap for the treatment of Parkinson's disease.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

July 07, 2022

Via Benzinga

83 Biggest Movers From Yesterday ↗

June 09, 2022

Gainers Symbotic Inc. (NASDAQ: SYM) shares surged 120.6% to settle at $20.07 on Wednesday. Symbotic reported the completion of its business combination with SVF Investment Corp. to become a publicly...

Via Benzinga

50 Stocks Moving In Wednesday's Mid-Day Session ↗

June 08, 2022

Gainers HeartCore Enterprises, Inc. (NASDAQ: HTCR) shares gained 81% to $1.8503 after the company authorized a $3.5 million buyback.

Via Benzinga

Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update

May 04, 2022

Berwyn, Pennsylvania--(Newsfile Corp. - May 4, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...

Via Newsfile

Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2022 ↗

May 02, 2022

Upgrades

Via Benzinga

The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid ↗

April 29, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging

April 28, 2022

Berwyn, Pennsylvania--(Newsfile Corp. - April 28, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...

Via Newsfile

Annovis Bio to Participate in World Parkinson's Day to Raise Awareness on the Debilitating Disease

April 11, 2022

Berwyn, Pennsylvania--(Newsfile Corp. - April 11, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...

Via Newsfile

Annovis Bio to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

March 23, 2022

Berwyn, Pennsylvania--(Newsfile Corp. - March 23, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...

Via Newsfile

Annovis Bio Presents at International Conference on Alzheimer's & Parkinson (AD/PD 2022)

March 18, 2022

Berwyn, Pennsylvania--(Newsfile Corp. - March 18, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...

Via Newsfile

Annovis Bio Announces Presentation at International Conference on Alzheimer's & Parkinson's Diseases 2022

March 08, 2022

Berwyn, Pennsylvania--(Newsfile Corp. - March 8, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...

Via Newsfile

Annovis Bio to Present at the Cowen 42nd Annual Health Care Conference

March 03, 2022

Berwyn, Pennsylvania--(Newsfile Corp. - March 3, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...

Via Newsfile

FDA Guides Annovis Bio For Two Phase 3 Buntanetap Trial In Parkinson's Disease ↗

January 25, 2022

Annovis Bio Inc (NYSE: ANVS) has completed a Type B meeting with the FDA regarding its planned Phase 3 studies of Buntanetap for the treatment of Parkinson's...

Via Benzinga

Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease

January 25, 2022

Berwyn, Pennsylvania--(Newsfile Corp. - January 25, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...

Via Newsfile

Annovis Bio Enhances Leadership Team with Two Senior Appointments

January 10, 2022

Company Appoints Eve Damiano, MS, RAC, as Senior Vice President of Regulatory OperationsCompany Promotes Cheng Fang, Ph.D., to Senior Vice...

Via Newsfile

Annovis Bio Announces Official Unique Name Buntanetap for Lead Candidate ANVS401

January 05, 2022

Berwyn, Pennsylvania--(Newsfile Corp. - January 5, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug...

Via Newsfile

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy